Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP)
Article first published online: 29 JUN 2010
Copyright © 2010 Wiley Periodicals, Inc.
Biotechnology and Bioengineering
Volume 107, Issue 4, pages 652–662, 1 November 2010
How to Cite
Müller-Späth, T., Krättli, M., Aumann, L., Ströhlein, G. and Morbidelli, M. (2010), Increasing the activity of monoclonal antibody therapeutics by continuous chromatography (MCSGP). Biotechnol. Bioeng., 107: 652–662. doi: 10.1002/bit.22843
- Issue published online: 13 SEP 2010
- Article first published online: 29 JUN 2010
- Manuscript Accepted: 10 JUN 2010
- Manuscript Revised: 7 JUN 2010
- Manuscript Received: 1 APR 2010
- monoclonal antibody;
- continuous chromatography;
- biological activity
The charged monoclonal antibody (mAb) variants of the commercially available therapeutics Avastin®, Herceptin® and Erbitux® were separated by ion-exchange gradient chromatography in batch and continuous countercurrent mode (MCSGP process). Different stationary phases, buffer conditions and two MCSGP configurations were used in order to demonstrate the broad applicability of MCSGP in the field of charged protein variant separation. Batch chromatography and MCSGP were compared with respect to yield, purity, and productivity. In the case of Herceptin®, also the biological activity of the product stream was taken into account as performance indicator. The robustness of the MCSGP process against feed composition variations was confirmed experimentally and by model simulations. Biotechnol. Bioeng. 2010;107:652–662. © 2010 Wiley Periodicals, Inc.